Introduction: It has been recognized for about 20 years that interleukin (IL)-1 signaling is implicated in Multiple Sclerosis (MS), a disabling, chronic, inflammatory and neurodegenerative disease of the central nervous system (CNS). Only recently, multifaceted roles of IL-1 emerged in MS pathophysiology as a result of both clinical and preclinical studies. Notably, drugs that directly target the IL-1 system have not been tested so far in MS.Areas covered: Recent studies in animal models, together with the development of ex vivo chimeric MS models, have disclosed a critical role for IL-1 not only at the peripheral level but also within the CNS. In the present review, we highlight the IL-1-dependent neuropathological aspects of MS, by providing an overview of the cells of the immune and CNS systems that respond to IL-1 signaling, and by emphasizing the subsequent effects on the CNS, from demyelinating processes, to synaptopathy, and excitotoxicity.Expert opinion: Drugs that act on the IL-1 system show a therapeutic potential in several autoinflammatory diseases and preclinical studies have highlighted the effects of these compounds in MS. We will discuss why anti-IL-1 therapies in MS have been neglected to date.

Musella, A., Fresegna, D., Rizzo, F.r., Gentile, A., De Vito, F., Caioli, S., et al. (2020). Prototypical proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting. EXPERT OPINION ON THERAPEUTIC TARGETS, 24(1), 37-46 [10.1080/14728222.2020.1709823].

Prototypical proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting

Musella, A;Fresegna, D;Rizzo, F. R;Gentile, A;Caioli, S;Guadalupi, L;Bruno, A;Dolcetti, E;Buttari, F;Bullitta, S;Centonze, D;
2020-01-01

Abstract

Introduction: It has been recognized for about 20 years that interleukin (IL)-1 signaling is implicated in Multiple Sclerosis (MS), a disabling, chronic, inflammatory and neurodegenerative disease of the central nervous system (CNS). Only recently, multifaceted roles of IL-1 emerged in MS pathophysiology as a result of both clinical and preclinical studies. Notably, drugs that directly target the IL-1 system have not been tested so far in MS.Areas covered: Recent studies in animal models, together with the development of ex vivo chimeric MS models, have disclosed a critical role for IL-1 not only at the peripheral level but also within the CNS. In the present review, we highlight the IL-1-dependent neuropathological aspects of MS, by providing an overview of the cells of the immune and CNS systems that respond to IL-1 signaling, and by emphasizing the subsequent effects on the CNS, from demyelinating processes, to synaptopathy, and excitotoxicity.Expert opinion: Drugs that act on the IL-1 system show a therapeutic potential in several autoinflammatory diseases and preclinical studies have highlighted the effects of these compounds in MS. We will discuss why anti-IL-1 therapies in MS have been neglected to date.
2020
Pubblicato
Rilevanza internazionale
Review
Esperti anonimi
Settore MED/26 - NEUROLOGIA
Settore MEDS-12/A - Neurologia
English
Con Impact Factor ISI
IL-1R; IL-1ra; IL-1α; IL-1β; demyelination; neurodegeneration; neuroinflammation; proinflammatory cytokines; synaptopathy
https://www.tandfonline.com/doi/abs/10.1080/14728222.2020.1709823?journalCode=iett20
Musella, A., Fresegna, D., Rizzo, F.r., Gentile, A., De Vito, F., Caioli, S., et al. (2020). Prototypical proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting. EXPERT OPINION ON THERAPEUTIC TARGETS, 24(1), 37-46 [10.1080/14728222.2020.1709823].
Musella, A; Fresegna, D; Rizzo, Fr; Gentile, A; De Vito, F; Caioli, S; Guadalupi, L; Bruno, A; Dolcetti, E; Buttari, F; Bullitta, S; Vanni, V; Centonz...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/239419
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 20
social impact